Ramonell Richard P, Gauthier Marc C, Ray Anuradha, Wenzel Sally E
Asthma and Environmental Lung Health Institute at UPMC, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA; email:
Annu Rev Med. 2025 Jan;76(1):339-355. doi: 10.1146/annurev-med-070323-103158. Epub 2025 Jan 16.
Asthma is a chronic inflammatory disease of the airways long known for phenotypic heterogeneity. Phenotyping studies in asthma have led to a better characterization of disease pathogenesis, yet further work is needed to pair available treatments with disease endotypes. In this review, the biology of targeted pathways is discussed along with the efficacy of biologic therapies targeting those pathways. Results of asthma clinical trials are included, as well as results of trials in related diseases. This review then analyzes how biologics help to inform the complex immunobiology of asthma and further guide their use while identifying areas for future research.
哮喘是一种气道慢性炎症性疾病，长期以来以表型异质性而闻名。哮喘的表型研究有助于更好地描述疾病发病机制，但仍需要进一步开展工作，以便将现有治疗方法与疾病内型相匹配。在本综述中，我们将讨论靶向通路的生物学特性以及针对这些通路的生物疗法的疗效。文中纳入了哮喘临床试验结果以及相关疾病的试验结果。本综述随后分析了生物制剂如何有助于揭示哮喘复杂的免疫生物学特性，并进一步指导其应用，同时确定未来的研究领域。
